SLAMF7 improves the efficacy of PD-1 immunotherapy by enhancing T cell response in non-small cell lung cancer
Programmed death-1 (PD-1) immune checkpoint inhibition has transformed the therapeutic landscape of non-small cell lung cancer (NSCLC), while a proportion of NSCLC cases exhibited primary or acquired resistance, reflecting the imperative to elucidate resistance mechanisms and identify synergistic im...
Збережено в:
| Автори: | , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Elsevier
2026-01-01
|
| Серія: | Immunobiology |
| Предмети: | |
| Онлайн доступ: | http://www.sciencedirect.com/science/article/pii/S017129852600001X |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|